BGE-102, an oral brain-penetrant NLRP3 inflammasome inhibitor: first participant dosed in the Phase 2 QUELL-CV trial

BioAge Labs, Inc.

1. 01

   First participant dosed June 2026 in Phase 2 QUELL-CV proof-of-concept

2. 02

   Three once-daily oral dose levels; primary readout is hsCRP dose-response

3. 03

   Population: obesity with elevated systemic inflammation and additional cardiovascular risk

4. 04

   Target nominated from human longevity datasets rather than disease-first screening

5. 05

   Topline data guided for H2 2026; a separate Phase 1b/2a in diabetic macular edema was planned for mid-2026

Study Design

Clinical Trial Update

Sample Size

Not reported

Study Duration

Not reported

Methodology

Phase 2 randomised proof-of-concept dose-ranging study; details as disclosed in company press releases and investor materials.

Limitations

Not peer-reviewed. All efficacy and safety characterisations are sponsor statements from press releases; no published Phase 1 or Phase 2 dataset is available. hsCRP is a surrogate, not a clinical outcome. Treat "best-in-class" framing as marketing until data are published.